Zentalis Pharmaceuticals Llc (ZNTL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zentalis Pharmaceuticals Llc stock (ZNTL) is currently trading at $2.55. Zentalis Pharmaceuticals Llc PS ratio (Price-to-Sales) is 5.95. Analyst consensus price target for ZNTL is $5.31. WallStSmart rates ZNTL as Sell.
- ZNTL PE ratio analysis and historical PE chart
- ZNTL PS ratio (Price-to-Sales) history and trend
- ZNTL intrinsic value — DCF, Graham Number, EPV models
- ZNTL stock price prediction 2025 2026 2027 2028 2029 2030
- ZNTL fair value vs current price
- ZNTL insider transactions and insider buying
- Is ZNTL undervalued or overvalued?
- Zentalis Pharmaceuticals Llc financial analysis — revenue, earnings, cash flow
- ZNTL Piotroski F-Score and Altman Z-Score
- ZNTL analyst price target and Smart Rating
Zentalis Pharmaceuticals Llc
📊 No data available
Try selecting a different time range
Smart Analysis
Zentalis Pharmaceuticals Llc (ZNTL) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Zentalis Pharmaceuticals Llc (ZNTL) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
61.96% held by institutions, strong professional interest
Supporting Valuation Data
Zentalis Pharmaceuticals Llc (ZNTL) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 6.0x annual revenue
Supporting Valuation Data
Zentalis Pharmaceuticals Llc (ZNTL) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.65) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Market Cap. Some valuation metrics including Price/Sales (5.95) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -49.20%, Operating Margin at -568.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -49.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZNTL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZNTL's Price-to-Sales ratio of 5.95x trades 92% above its historical average of 3.1x (76th percentile), historically expensive. The current valuation is 10% below its historical high of 6.63x set in Mar 2026, and 427% above its historical low of 1.13x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~1.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zentalis Pharmaceuticals Llc (ZNTL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Zentalis Pharmaceuticals Llc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.15 indicates a conservative balance sheet with 39M in cash.
Spending 85% of revenue (23M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -27M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.71, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Zentalis Pharmaceuticals Llc.
Bottom Line
Zentalis Pharmaceuticals Llc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Zentalis Pharmaceuticals Llc(ZNTL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.